| 摘要 |
Provided herein are pharmaceutical compositions comprising one or more muscarinic receptor antagonists ("MRA"), and at least one additional active ingredients selected from one or more beta2-agonists, p38 MAP kinase inhibitors, PDE-IV inhibitors, corticosteroids or a mixture thereof and optionally one or more pharmaceutically acceptable carriers, excipients or diluents. In addition, methods of treating autoimmune, inflammatory or allergic diseases or disorders are provided.
|
